Evan Bauman, co-manager of the $3.2bn (£2bn) Legg Mason ClearBridge US Aggressive Growth fund, is still seeing value in blue-chip biotechnology firms in the US despite the huge rally in the wider sector.
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
